Compare Orchid Chemicals with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs PIRAMAL ENTERPRISES - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD PIRAMAL ENTERPRISES ORCHID PHARMA LTD/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -0.5 16.9 - View Chart
P/BV x 0.1 1.1 10.5% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 ORCHID PHARMA LTD   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
PIRAMAL ENTERPRISES
Mar-19
ORCHID PHARMA LTD/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1943,303 5.9%   
Low Rs351,797 1.9%   
Sales per share (Unadj.) Rs276.5716.5 38.6%  
Earnings per share (Unadj.) Rs-79.279.7 -99.4%  
Cash flow per share (Unadj.) Rs-43.5107.9 -40.3%  
Dividends per share (Unadj.) Rs028.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs53.91,477.5 3.7%  
Shares outstanding (eoy) m70.45184.45 38.2%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x0.43.6 11.6%   
Avg P/E ratio x-1.432.0 -4.5%  
P/CF ratio (eoy) x-2.623.6 -11.2%  
Price / Book Value ratio x2.11.7 123.0%  
Dividend payout %035.1 0.0%   
Avg Mkt Cap Rs m8,067470,292 1.7%   
No. of employees `0002.87.8 35.8%   
Total wages/salary Rs m2,52722,504 11.2%   
Avg. sales/employee Rs Th6,956.116,899.4 41.2%   
Avg. wages/employee Rs Th902.52,877.7 31.4%   
Avg. net profit/employee Rs Th-1,993.01,879.9 -106.0%   
INCOME DATA
Net Sales Rs m19,477132,153 14.7%  
Other income Rs m4073,128 13.0%   
Total revenues Rs m19,884135,281 14.7%   
Gross profit Rs m1,10366,290 1.7%  
Depreciation Rs m2,5195,202 48.4%   
Interest Rs m5,22744,097 11.9%   
Profit before tax Rs m-6,23620,119 -31.0%   
Minority Interest Rs m203,194 0.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1258,611 -1.5%   
Profit after tax Rs m-5,58014,701 -38.0%  
Gross profit margin %5.750.2 11.3%  
Effective tax rate %2.042.8 4.7%   
Net profit margin %-28.711.1 -257.5%  
BALANCE SHEET DATA
Current assets Rs m11,014122,742 9.0%   
Current liabilities Rs m32,060310,810 10.3%   
Net working cap to sales %-108.1-142.3 75.9%  
Current ratio x0.30.4 87.0%  
Inventory Days Days9523 411.3%  
Debtors Days Days3439 86.4%  
Net fixed assets Rs m29,440116,904 25.2%   
Share capital Rs m705369 191.0%   
"Free" reserves Rs m2,043272,161 0.8%   
Net worth Rs m3,800272,530 1.4%   
Long term debt Rs m9,018270,196 3.3%   
Total assets Rs m46,510856,261 5.4%  
Interest coverage x-0.21.5 -13.3%   
Debt to equity ratio x2.41.0 239.4%  
Sales to assets ratio x0.40.2 271.3%   
Return on assets %-0.86.9 -11.1%  
Return on equity %-146.95.4 -2,722.4%  
Return on capital %-3.712.4 -30.1%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51315,200 49.4%   
Fx outflow Rs m5,6494,889 115.5%   
Net fx Rs m1,86510,312 18.1%   
CASH FLOW
From Operations Rs m1,682-115,975 -1.5%  
From Investments Rs m-9,860-8,265 119.3%  
From Financial Activity Rs m6,644107,525 6.2%  
Net Cashflow Rs m-1,535-16,650 9.2%  

Share Holding

Indian Promoters % 32.3 52.9 61.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 4.0 115.0%  
FIIs % 3.3 26.6 12.4%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 16.5 335.2%  
Shareholders   84,811 93,274 90.9%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Up; Telecom Stocks Rally(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.6% while the Hang Seng is up 0.9%.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS